Structure Therapeutics Inc (GPCR)
34.17
-3.52
(-9.34%)
USD |
NASDAQ |
Nov 15, 16:00
34.18
0.00 (0.00%)
After-Hours: 20:00
Structure Therapeutics Research and Development Expense (TTM): 80.29M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 80.29M |
| March 31, 2024 | 77.65M |
| December 31, 2023 | 70.10M |
| September 30, 2023 | 58.42M |
| Date | Value |
|---|---|
| June 30, 2023 | 50.07M |
| March 31, 2023 | 40.84M |
| December 31, 2022 | 36.19M |
| September 30, 2022 | 37.74M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
36.19M
Minimum
Dec 2022
80.29M
Maximum
Jun 2024
56.41M
Average
54.24M
Median
Research and Development Expense (TTM) Benchmarks
| Viking Therapeutics Inc | 91.16M |
| Eli Lilly and Co | 10.53B |
| Novo Nordisk AS | 6.495B |
| Pfizer Inc | 10.60B |
| Amgen Inc | 5.774B |